Die Rolle von Phytotherapie bei COVID-19-assoziierter Angst und Depression

Zusammenfassung

Der vorliegende Artikel bietet einen Überblick über die Anwendung von Phytotherapie bei psychiatrischen Manifestationen, die im Kontext von COVID-19 aufgetreten sind. Insbesondere wird der Einsatz des mit eigenen Anteilen angereicherten Lavendelöls Silexan^® (aus Lavandula angustifolia Mill.), des aus Ginkgo (Ginkgo biloba L.) hergestellten Extraktes EGb 761^® sowie des Extraktes SHR-5 aus Rosenwurz (Rhodiola rosea L.) beleuchtet, die bereits Erfolge in der Behandlung von vordergründig milden Angstzuständen, depressiven, psychosomatischen und kognitiven Symptomen zeigten. Diese zählen zu den am häufigsten auftretenden Beschwerden im Rahmen des sog. Long-COVID-Syndroms.

Im Detail stellen wir 4 Fälle vor, die unsere ersten klinischen Erfahrungen mit Silexan^® bei erwachsenen ambulanten Patienten mit sowohl subsyndromalen als auch voll ausgeprägten Angsterkrankungen und depressiven Zustandsbildern illustrieren, die in Zusammenhang mit COVID-19 aufgetreten sind. In Anbetracht der langfristigen negativen Auswirkungen auf die Gesundheit, Lebensqualität und Funktionalität der Betroffenen, denen durch eine frühe diagnostische Zuordnung und eine rechtzeitige adäquate Behandlung vorgebeugt werden kann, scheint ein evidenzbasierter Einsatz von Phytotherapie in der Behandlung von COVID-19-assoziierten psychiatrischen Manifestationen, die vor allem subsyndromale Ausprägung aufweisen, eine wichtige und klinisch sehr relevante Rolle zu spielen.

Abstract

This article provides an overview of the evidence-based administration of phytotherapy for psychiatric manifestations that have occurred in the context of COVID-19. In particular, we focus on a modified lavender oil enriched by its own components Silexan^® (Lavandula angustifolia Mill.), the extract EGb 761^® derived from ginkgo (Ginkgo biloba L.) as well as the extract SHR-5 from rose root (Rhodiola rosea L.), which have already shown success in the treatment of anxiety, depressive, psychosomatic, and cognitive symptoms, especially of the so-called subthreshold or subsyndromal extent. Importantly, subsyndromal manifestations of these psychiatric conditions rank among the most frequently occurring complaints in the context of the so-called Long COVID syndrome.

Here, we present four cases that illustrate our initial clinical experience with Silexan^® in adult outpatients with both subsyndromal and full-blown anxiety and depression with accompanying psychosomatic and cognitive symptoms that have occurred in the context of COVID-19. Considering the long-term negative effects on the health, quality of life and functionality of patients affected by these symptoms, which can be prevented by early diagnosis and timely and adequate treatment, the evidence-based use of phytotherapy appears to play an important and clinically relevant role in the treatment of COVID-19-associated psychiatric manifestations, which are mainly subsyndromal in nature.

Keywords

COVID-19 - anxiety - depression - subsyndromal - phytotherapy - Silexan^®

Schlüsselwörter

COVID-19 - Angst - Depression - subsyndromal - Phytotherapie - Silexan^®

Publication History

Article published online:
13 August 2024

• Literatur

• 1 Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz (BMSGPK). ICD-10. BMSGPK 2024 – Systematisches Verzeichnis. 2024
• 2 Jacobson KB, Rao M, Bonilla H. et al. Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clin Infect Dis 2021; 73: e826-e829
• 3 Peter RS, Nieters A, Kräusslich HG. et al. EPILOC Phase 1 Study Group. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ 2022; 379: e071050
• 4 Zürcher SJ, Banzer C, Adamus C. et al. Post-viral mental health sequelae in infected persons associated with COVID-19 and previous epidemics and pandemics: Systematic review and meta-analysis of prevalence estimates. J Infect Public Health 2022; 15: 599-608
• 5 Volz HP, Saliger J, Kasper S. et al. Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey. Int J Psychiatry Clin Pract 2022; 26: 277-286
• 6 Volz HP, Stirnweiß J, Kasper S. et al. Subthreshold depression – concept, operationalisation and epidemiological data. A scoping review. Int J Psychiatry Clin Pract 2023; 27: 92-106
• 7 Ida FS, Ferreira HP, Vasconcelos AKM. et al. Post-COVID-19 syndrome: persistent symptoms, functional impact, quality of life, return to work, and indirect costs – a prospective case study 12 months after COVID-19 infection. Cad Saúde Pública 2024; 40: e00022623
• 8 Malesevic S, Sievi NA, Baumgartner P. et al. Impaired health-related quality of life in long-COVID syndrome after mild to moderate COVID-19. Sci Rep 2023; 13: 7717
• 9 Bartova L, Dold M, Volz HP. et al. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. Eur Arch Psychiatry Clin Neurosci 2022; 273: 51-63
• 10 Sarris J, Ravindran A, Yatham LN. et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry 2022; 23: 424-455
• 11 Bartova L, Dold M, Fugger G. et al. Silexan for treatment of anxiety and depression in the context of COVID-19. Eur Neuropsychopharmacol 2023; 70: 47-48
• 12 Kasper S, Volz HP, Möller HJ. et al. Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial. Eur Arch Psychiatry Clin Neurosci 2024; [Online ahead of print]
• 13 Dold M, Bartova L, Volz HP. et al. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 2023; 273: 1615-1628
• 14 Mueller JK, Müller WE. Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea . J Neural Transm 2024; 131: 203-212
• 15 Kasper S, Eckert A, Möller HJ. et al. Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan. Int J Psychiatry Clin Pract 2023; 27: 285-291
• 16 Ihl R, Frölich L, Winblad B. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry 2011; 12: 2-32
• 17 Grass-Kapanke B, Busmane A, Lasmanis A. et al. Effects of Ginkgo biloba special extract EGb 761^® in very mild cognitive impairment (vMCI). Neurosci Med 2011; 2: 48-56
• 18 Gschwind YJ, Bridenbaugh SA, Reinhard S. et al. Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study. Aging Clin Exp Res 2017; 29: 609-619
• 19 Zifko U, Guendling K, Seet R. et al. Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care. Front Pharmacol 2024; 15: 1338235
• 20 Liu X, Hao W, Qin Y. et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer’s disease. Brain Behav Immun 2015; 46: 121-131
• 21 Kasper S, Bancher C, Eckert A. et al. Management of mild cognitive impairment (MCI): The need for national and international guidelines. World J Biol Psychiatry 2020; 21: 579-594
• 22 Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Ginkgo biloba L., folium. EMA/HMPC/321097/2012
• 23 Anghelescu IG, Edwards D, Seifritz E. et al. Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract 2018; 22: 242-252
• 24 Lee Y, Jung J-C, Jang S. et al. Anti-inflammatory and neuroprotective effects of constituents isolated from Rhodiola rosea . Evid Based Complement Alternat Med 2013; 2013: 514049
• 25 Dold M, Möller HJ, Volz HP. et al. Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials. Eur Psychiatry 2024; 67: e23
• 26 Baldinger P, Höflich AS, Mitterhauser M. et al. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol 2014; 18: pyu063
• 27 Baldinger-Mehlich P, Spies M, Lanzeberger R, Kasper S. Der Stellenwert der Phytomedizin in der Psychiatrie. CliniCum neuropsy. 01/2018. https://oegpb.at/2018/04/04/der-stellenwert-der-phytomedizin-in-der-psychiatrie
• 28 Friedland K, Silani G, Schuwald A. et al. Neurotrophic properties of Silexan, an essential oil from the flowers of lavender--preclinical evidence for antidepressant-like properties. Pharmacopsychiatry 2021; 54: 37-46
• 29 Müller WE, Sillani G, Schuwald A. et al. Pharmacological basis of the anxiolytic and antidepressant properties of Silexan^®, an essential oil from the flowers of lavender. Neurochem Int 2021; 143: 104899
• 30 Möller HJ, Volz HP, Dienel A. et al. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 2019; 269: 183-193
• 31 von Känel R, Kasper S, Bondolfi G. et al. Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. Brain Behav 2021; 11: e01997
• 32 Kasper S, Möller HJ, Volz HP. et al. Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. Int Clin Psychopharmacol 2017; 32: 195-204
• 33 Kasper S, Volz HP, Dienel A. et al. Efficacy of Silexan in mixed anxiety-depression – A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2016; 26: 331-340
• 34 Kasper S, Anghelescu I, Dienel A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015; 25: 1960-1967
• 35 Kasper S. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. Int J Psychiatry Clin Pract 2013; 17: 15-22
• 36 Seifritz E, Schläfke S, Holsboer-Trachsler E. Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect. J Psychiatr Res 2019; 115: 69-74
• 37 Kasper S, Gastpar M, Müller WE. et al. Efficacy and safety of Silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials. Wien Med Wochenschr 2010; 160: 547-556
• 38 Yap WS, Dolzhenko AV, Jalal Z. et al. Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis. Sci Rep 2019; 9: 18042
• 39 Lavendelöl. [Pflanzliche Stoffe und Zubereitungen: Zusammenfassung für die Öffentlichkeit]. EMA/HMPC/530968/2012.
• 40 COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; 398: 1700-1712
• 41 Zifko UA, Yacob M, Braun BJ. et al. Alleviation of post-COVID-19 cognitive deficits by treatment with EGb 761^®: A case series. Am J Case Rep 2022; 23: e937094
• 42 Taquet M, Dercon Q, Luciano S. et al. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021; 18: e1003773
• 43 Doykov I, Hällqvist J, Gilmour KC. et al. ’The long tail of Covid-19’ - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res 2020; 9: 1349
• 44 Kasper S, Gastpar M, Müller WE. et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 2010; 25: 277-287
• 45 Kasper S, Gastpar M, Müller WE. et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 2014; 17: 859-869
• 46 Möller H-J, Volz H-P, Seifritz E. et al. Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. J Psychiatr Res 2021; 136: 543-551
• 47 Seifritz E, Möller HJ, Volz HP. et al. No abuse potential of Silexan in healthy recreational drug users: A randomized controlled trial. Int J Neuropsychopharmacol 2021; 24: 171-180
• 48 Bartova L, Fugger G, Dold M. et al. Therapieoptionen bei Angsterkrankungen unter Berücksichtigung der Phyto-Psychopharmakotherapie // Treatment Strategies of Anxiety Disorders: The Role of Phyto-Psychopharmacotherapy. Journal für Neurologie. Neurochirurgie und Psychiatrie 2022; 23: 124-130
• 49 Fenton C, Lee A. Antidepressants with anti-inflammatory properties may be useful in long COVID depression. Drugs Ther Perspect 2023; 39: 65-70
• 50 Victor MM, Müller Haas L, Grevet EH. et al. Successful treatment of post-COVID-19 ADHD-like syndrome: A case report. J Atten Disord 2023; 27: 1092-1098
• 51 Mahdi M, Hermán L, Réthelyi JM. et al. Potential role of the antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19. Int J Mol Sci 2022; 23: 3812
• 52 Reinfeld S. Can bupropion treat COVID-19-induced brain fog? A case series. Int Clin Psychopharmacol 2023; 38: 189-191